Literature DB >> 28783169

Glioblastoma stem cells exploit the αvβ8 integrin-TGFβ1 signaling axis to drive tumor initiation and progression.

P A Guerrero1, J H Tchaicha1, Z Chen1, J E Morales1, N McCarty2, Q Wang3,4, E P Sulman3,4,5, G Fuller6, F F Lang1, G Rao1, J H McCarty1.   

Abstract

Glioblastoma (GBM) is a primary brain cancer that contains populations of stem-like cancer cells (GSCs) that home to specialized perivascular niches. GSC interactions with their niche influence self-renewal, differentiation and drug resistance, although the pathways underlying these events remain largely unknown. Here, we report that the integrin αvβ8 and its latent transforming growth factor β1 (TGFβ1) protein ligand have central roles in promoting niche co-option and GBM initiation. αvβ8 integrin is highly expressed in GSCs and is essential for self-renewal and lineage commitment in vitro. Fractionation of β8high cells from freshly resected human GBM samples also reveals a requirement for this integrin in tumorigenesis in vivo. Whole-transcriptome sequencing reveals that αvβ8 integrin regulates tumor development, in part, by driving TGFβ1-induced DNA replication and mitotic checkpoint progression. Collectively, these data identify the αvβ8 integrin-TGFβ1 signaling axis as crucial for exploitation of the perivascular niche and identify potential therapeutic targets for inhibiting tumor growth and progression in patients with GBM.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28783169      PMCID: PMC5882487          DOI: 10.1038/onc.2017.248

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  69 in total

1.  Cancer: The nuances of therapy.

Authors:  Lee M Ellis; David A Reardon
Journal:  Nature       Date:  2009-03-19       Impact factor: 49.962

2.  Cilengitide in patients with recurrent glioblastoma: the results of NABTC 03-02, a phase II trial with measures of treatment delivery.

Authors:  Mark R Gilbert; John Kuhn; Kathleen R Lamborn; Frank Lieberman; Patrick Y Wen; Minesh Mehta; Timothy Cloughesy; Andrew B Lassman; Lisa M Deangelis; Susan Chang; Michael Prados
Journal:  J Neurooncol       Date:  2011-07-08       Impact factor: 4.130

3.  Excessive vascular sprouting underlies cerebral hemorrhage in mice lacking αVβ8-TGFβ signaling in the brain.

Authors:  Thomas D Arnold; Colin Niaudet; Mei-Fong Pang; Julie Siegenthaler; Konstantin Gaengel; Bongnam Jung; Gina M Ferrero; Yoh-suke Mukouyama; Jonas Fuxe; Rosemary Akhurst; Christer Betsholtz; Dean Sheppard; Louis F Reichardt
Journal:  Development       Date:  2014-11-18       Impact factor: 6.868

4.  Glioblastoma angiogenesis and tumor cell invasiveness are differentially regulated by β8 integrin.

Authors:  Jeremy H Tchaicha; Steve B Reyes; Jaekyung Shin; Mohammad G Hossain; Frederick F Lang; Joseph H McCarty
Journal:  Cancer Res       Date:  2011-08-22       Impact factor: 12.701

5.  Microarray-based copy number analysis of neurofibromatosis type-1 (NF1)-associated malignant peripheral nerve sheath tumors reveals a role for Rho-GTPase pathway genes in NF1 tumorigenesis.

Authors:  Meena Upadhyaya; Gill Spurlock; Laura Thomas; Nick S T Thomas; Mark Richards; Viktor-Felix Mautner; David N Cooper; Abhijit Guha; Jim Yan
Journal:  Hum Mutat       Date:  2012-03-05       Impact factor: 4.878

6.  High TGFbeta-Smad activity confers poor prognosis in glioma patients and promotes cell proliferation depending on the methylation of the PDGF-B gene.

Authors:  Alejandra Bruna; Rachel S Darken; Federico Rojo; Alberto Ocaña; Silvia Peñuelas; Alexandra Arias; Raquel Paris; Avelina Tortosa; Jaume Mora; Jose Baselga; Joan Seoane
Journal:  Cancer Cell       Date:  2007-02       Impact factor: 31.743

7.  A mosaic mouse model of astrocytoma identifies alphavbeta8 integrin as a negative regulator of tumor angiogenesis.

Authors:  J H Tchaicha; A K Mobley; M G Hossain; K D Aldape; J H McCarty
Journal:  Oncogene       Date:  2010-06-07       Impact factor: 9.867

8.  Mir-21-Sox2 Axis Delineates Glioblastoma Subtypes with Prognostic Impact.

Authors:  Pratheesh Sathyan; Pascal O Zinn; Anantha L Marisetty; Bin Liu; Mohamed Mostafa Kamal; Sanjay K Singh; Pierre Bady; Li Lu; Khalida M Wani; Bethany L Veo; Joy Gumin; Dina Hamada Kassem; Frederick Robinson; Connie Weng; Veerabhadran Baladandayuthapani; Dima Suki; Howard Colman; Krishna P Bhat; Erik P Sulman; Ken Aldape; Rivka R Colen; Roel G W Verhaak; Zhimin Lu; Gregory N Fuller; Suyun Huang; Frederick F Lang; Raymond Sawaya; Monika Hegi; Sadhan Majumder
Journal:  J Neurosci       Date:  2015-11-11       Impact factor: 6.167

9.  αvβ8 integrin interacts with RhoGDI1 to regulate Rac1 and Cdc42 activation and drive glioblastoma cell invasion.

Authors:  Steve B Reyes; Anjana S Narayanan; Hye Shin Lee; Jeremy H Tchaicha; Kenneth D Aldape; Frederick F Lang; Kimberly F Tolias; Joseph H McCarty
Journal:  Mol Biol Cell       Date:  2013-01-02       Impact factor: 4.138

10.  ABCG2 regulates self-renewal and stem cell marker expression but not tumorigenicity or radiation resistance of glioma cells.

Authors:  Boyoung Wee; Alexander Pietras; Tatsuya Ozawa; Elena Bazzoli; Ondrej Podlaha; Christophe Antczak; Bengt Westermark; Sven Nelander; Lene Uhrbom; Karin Forsberg-Nilsson; Hakim Djaballah; Franziska Michor; Eric C Holland
Journal:  Sci Rep       Date:  2016-07-26       Impact factor: 4.379

View more
  16 in total

1.  FHL3 links cell growth and self-renewal by modulating SOX4 in glioma.

Authors:  Wei Han; Peishan Hu; Fan Wu; Shanshan Wang; Yan Hu; Shanshan Li; Tao Jiang; Boqin Qiang; Xiaozhong Peng
Journal:  Cell Death Differ       Date:  2018-06-28       Impact factor: 15.828

Review 2.  αvβ8 integrin adhesion and signaling pathways in development, physiology and disease.

Authors:  Joseph H McCarty
Journal:  J Cell Sci       Date:  2020-06-15       Impact factor: 5.285

Review 3.  The complex relationship between integrins and oncolytic herpes Simplex Virus 1 in high-grade glioma therapeutics.

Authors:  Kimberly Ann Rivera-Caraballo; Mitra Nair; Tae Jin Lee; Balveen Kaur; Ji Young Yoo
Journal:  Mol Ther Oncolytics       Date:  2022-06-06       Impact factor: 6.311

Review 4.  A Conceptual Framework for Inducing T Cell-Mediated Immunity Against Glioblastoma.

Authors:  Sascha Marx; Anze Godicelj; Kai W Wucherpfennig
Journal:  Semin Immunopathol       Date:  2022-05-03       Impact factor: 11.759

5.  PTPN12/PTP-PEST Regulates Phosphorylation-Dependent Ubiquitination and Stability of Focal Adhesion Substrates in Invasive Glioblastoma Cells.

Authors:  Zhihua Chen; John E Morales; Paola A Guerrero; Huandong Sun; Joseph H McCarty
Journal:  Cancer Res       Date:  2018-05-09       Impact factor: 12.701

6.  Screening and authentication of molecular markers in malignant glioblastoma based on gene expression profiles.

Authors:  Yang-Fan Zou; Ling-Bing Meng; Zhao-Kai He; Chen-Hao Hu; Meng-Jie Shan; Deng-Yuan Wang; Xin Yu
Journal:  Oncol Lett       Date:  2019-09-04       Impact factor: 2.967

7.  Integrin αvβ8 serves as a Novel Marker of Poor Prognosis in Colon Carcinoma and Regulates Cell Invasiveness through the Activation of TGF-β1.

Authors:  Mingliang Zhou; Jun Niu; Jinshen Wang; Huijie Gao; Muhammad Shahbaz; Zhengchuan Niu; Zequn Li; Xueqing Zou; Benjia Liang
Journal:  J Cancer       Date:  2020-04-06       Impact factor: 4.207

8.  Serum amyloid A1 in combination with integrin αVβ3 increases glioblastoma cells mobility and progression.

Authors:  Ching-Yu Lin; Shun-Tai Yang; Shing-Chuan Shen; Yi-Chen Hsieh; Fei-Ting Hsu; Cheng-Yu Chen; Yung-Hsiao Chiang; Jian-Ying Chuang; Kai-Yun Chen; Tsung-I Hsu; Wan-Chong Leong; Yu-Kai Su; Wei-Lun Lo; Yi-Shian Yeh; Yudha Nur Patria; Hsiu-Ming Shih; Che-Chang Chang; Szu-Yi Chou
Journal:  Mol Oncol       Date:  2018-04-17       Impact factor: 6.603

9.  Identification of integrin drug targets for 17 solid tumor types.

Authors:  Adith S Arun; Clifford G Tepper; Kit S Lam
Journal:  Oncotarget       Date:  2018-07-10

10.  Megalencephalic leukoencephalopathy with subcortical cysts 1 (MLC1) promotes glioblastoma cell invasion in the brain microenvironment.

Authors:  John M Lattier; Arpan De; Zhihua Chen; John E Morales; Frederick F Lang; Jason T Huse; Joseph H McCarty
Journal:  Oncogene       Date:  2020-10-10       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.